# The Impact of Acute Dynamic Exercise on Intraocular Pressure: Role of the $\beta_2$ -adrenergic Receptor Polymorphism

K Güngör<sup>1</sup>, H Beydağı<sup>2</sup>, N Bekir<sup>1</sup>, C Arslan<sup>3</sup>, C Süer<sup>4</sup>, İ Erbağcı<sup>1</sup>, T Ergenoğlu<sup>2</sup> and AŞ Aynacıoğlu<sup>5</sup>

<sup>1</sup>Medical Faculty, Department of Ophthalmology, Gaziantep University, Gaziantep, Turkey; <sup>2</sup>Medical Faculty, Department of Physiology, Mersin University, Mersin, Turkey; <sup>3</sup>Physical Education and Sports School, Gaziantep University, Gaziantep, Turkey; <sup>4</sup>Medical Faculty, Department of Physiology, Erciyes University, Kayseri, Turkey; <sup>5</sup>Medical Faculty, Department of Pharmacology, Pamukkale University, Denizli, Turkey

Effects of mutations in the  $\beta_2$ -adrenergic receptor ( $\beta_2AR$ ) gene on intraocular pressure (IOP), in response to acute dynamic exercise, were investigated in 19 healthy males (age 22.6 ± 2.8 years). Intraocular pressures were measured pre- and postexercise. Weight, height, body mass index, and maximal oxygen (VO<sub>2max</sub>) uptake were recorded and subjects were genotyped for Arg16Gly, Gln27Glu and Thr164Ile mutations of the  $\beta_2AR$  gene. Post-exercise, reductions in mean IOP values were found in 16 subjects with the Gly16Gly and Arg16Gly genotypes, but these values remained low in the eight patients with the Gly16Gly genotype 3 h post-exercise, whereas they returned to baseline within 1 h in the eight subjects with the Arg16Gly genotype.  $\beta_2AR$  stimulation during exercise could be an important regulator of IOP response and determining  $\beta_2AR$  polymorphisms may improve understanding of pathogenesis and treatment selection in ophthalmic diseases, e.g. glaucoma.

```
KEY WORDS: Glaucoma; Intraocular pressure; \beta_2-adrenergic receptor;
Polymorphism; Exercise
```

## Introduction

The impact of dynamic exercise conditioning on intraocular pressure (IOP) is not fully understood, although transient reductions in IOP produced by acute dynamic exercise are well documented.<sup>1,2</sup> Some experimental and clinical studies imply that combining exercise conditioning with medical therapy may decrease IOP in glaucoma patients.<sup>1 – 5</sup> Numerous mechanisms of action have been postulated to explain the IOP-drop associated with acute, dynamic exercise, including changes in episcleral venous pressure, plasma lactate levels, blood pH, plasma osmolarity and hormone levels.<sup>5–11</sup> Activation of the sympathetic nervous system during exercise has already been shown to cause a seven-fold increase in circulating catecholamines in plasma.<sup>12,13</sup>  $\beta_2$ adrenergic receptor ( $\beta_2$ AR) sites have been demonstrated in non-pigmented ciliary epithelial cells, human trabecular meshwork cells, and retinal vessels, and most of these receptor sites are of the  $\beta_2$ AR type.<sup>14 - 16</sup>

The  $\beta_2$ ARs belong to the superfamily of G-protein-coupled receptors, with amino terminus localized extracellularly, seven transmembrane-spanning domains, and an intracellular carboxyl-terminus.<sup>17</sup> The coding region of the  $\beta_2AR$  was first investigated by Kobilka et al.18 and is located on chromosome 5q31. Three polymorphic  $\beta_2$ ARs have been studied in some detail and display altered receptor function in vitro.<sup>19</sup> Wild-type  $\beta_2$ ARs contain Arg16, Gln27, and Thr164. Compared to their wild types, mutant  $\beta_2$ ARs display different receptor–effector interactions, namely Gly versus Arg at codon 16, Glu versus Gln at codon 27, and Ile versus Thr at codon 164.<sup>20,21</sup> All three polymorphisms appear to alter receptor function, and the airways of individuals with these receptors are likely to behave differently when exposed to circulating catecholamines or exogenous drugs.<sup>19</sup> The Gly16 form of the receptor down-regulates following exposure to an agonist, to a much greater extent than the Arq16 form, in both transfected cell systems and in primary cultured human airway smooth-muscle cells.<sup>22</sup> The Glu27 form exhibits a protective effect against down-regulation, in both transfected and non-transfected cell systems.<sup>22,23</sup>

No previous study has investigated the impact of dynamic exercise on IOP regarding the  $\beta_2AR$  gene polymorphism. As a result, we explored whether a relationship exists between these gene mutations and the IOP response to acute dynamic exercise.

## Materials and methods

### PARTICIPANTS

Nineteen healthy male adult students (mean age,  $22.6 \pm 2.8$  years) volunteered to participate in this study. Before enrolment, each underwent a preliminary examination, including slit-lamp, gonioscopic, ophthalmoscopic and

refractive error evaluation. No ocular pathology was seen. The subjects also had no history of systemic or ocular diseases and were not using topical or systemic medications.

#### PROCEDURE

Volunteers performed exercise testing in the form of a 20 m Shuttle Run Test (Endurance Shuttle Run Test). They ate  $\geq 2$  h before the test, ambient temperature was 21°C, no warm-up exercises were allowed and each participant had a 10-min rest in the supine position before testing started at 09.00. Testing began at walking pace, with subjects moving between lines 20 m apart. A sound signal dictated changes of direction and pace, which gradually got faster: each subject scored a successful lap when they crossed the end line with at least one foot when, or shortly before, the signal sounded. Failure to reach the end line more than once in succession before the sound indicated that the subject could not maintain the required pace. The individual score was then taken as the lap number at which the second successive failure occurred, or as the number of the last completed lap if a subject stopped. The maximal oxygen uptake (VO<sub>2max</sub>) value of each subject was estimated as an indicator of individual cardio-respiratory endurance, using a table prepared for this test.

For each subject, IOPs were measured with a Perkins hand applanation tonometer (Clement Clarke International Ltd, Harlow, UK) pre- and immediately post-exercise, at 10.00, 12.00 and 16.00, after instilling one drop of benoxinate hydrochloride 0.2%, and fluorescein sodium 0.25% in each eye. All IOP measurements were performed by the same person, beginning with the right eye. Body weight (kg), height (cm), body mass index (kg/m<sup>2</sup>), and VO<sub>2max</sub> were recorded for each subject.

#### GENOTYPING

The mutation sites of the  $\beta_2AR$  gene were identified by polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) analysis.<sup>24</sup> The PCR reactions were undertaken in a total volume of 25 µl, containing specified amounts of DNA as template, 0.2 µmol/l of each primer (all primers were synthesized by TIB Molbiol, Berlin, Germany), 0.5 U Taq-DNA polymerase (Gibco, New Zealand), 0.2 mmol/L of each dNTP (Boehringer-Mannheim, Germany), 10 mmol/l Tris-HCl (pH 8.8), 50 mmol/l KCl, and 1.5 mmol/l MqCl<sub>2</sub>. A 242 base pair (bp) fragment, including both the polymorphic sites at codon 16 and 27, was amplified using primers 5'-GAACGGCAGCGCCTTCTTGCTGGCACC-CCAT (sense, AB3) and 5'-CTGCCAGG CCCATGACCAGATCAG (anti-sense, AB2). Compared with the natural sequence of the  $\beta_2$ AR, the underlined C was changed from A to C, to generate a polymorphism-specific restriction site. Conditions for PCR were as follows: 2 min initial denaturation at 94 °C, 35 cycles of amplification (denaturation 94°C, 30 s; primer annealing 64°C, 45 s; polymerization 72°C, 1 min) followed by final elongation (7 min, 72 °C), undertaken using a thermal cycler (9700 PCRthermocycler, Perkin Elmer, USA). The PCR products were separated into two tubes, each containing 10 µl aliquots. To detect the Arq16Gly polymorphism, overnight digestion at 37 °C with 10 U Eco130I (Fermentas, St Leon-Rot, Germany) was

performed in one tube of the PCR product, whereas presence of the Gln27Glu polymorphism was identified in the second tube using 10 U Fnu4HI (New England BioLabs, Frankfurt, Germany). To evaluate the mutation at codon 164, a second PCR procedure was performed, generating 280 bp fraament with primers a 5'-GTGATCGCAGTGGA-TCGCTACT (sense, AB4) and 5'-AGACGAAGACCATGATCACCAG (anti-sense, AB5) under the conditions described above, except primer annealing was at 58 °C. Again, 10 µl of the PCR product was digested by 10 U Mn1I (New England BioLabs). All RFLP fragments were separated on a 3% 3:1 NuSieve-agarose gel and documented with a still video system (Vilber Lourmat, Torcy, France).

#### STATISTICAL ANALYSIS

Statistical analyses were undertaken using Wilcoxon matched-pair signed-rank test for dependent groups and one-way ANOVA test for independent groups, with P < 0.05 regarded as statistically significant. All computations were made using SPSS software (SPSS Inc., Illinois, USA).

## Results

Results of the 20 m Shuttle Run Test showed that all participants had good  $VO_{2max}$  values and were designated physically fit subjects.

Table 1 shows the  $\beta_2AR$  genotype distribution among subjects according to results of the PCR-RFLP. Polymorphisms of

TABLE 1: $\beta_2$ -adrenergic receptor genotype distribution of subjects ( <i>n</i> = 19)					
	Arg16Gly	Gln27Glu	Thr164lle		
0 (wild type)	3	11	19		
1 (heterozygote mutant)	8	5	-		
2 (homozygote mutant)	8	3	-		

Gln27Glu and Thr164Ile were studied, but appropriate genotype distribution could not be provided, therefore statistical analyses of these polymorphisms were not performed.

Results of the PCR-RFLP identified three subjects with Arg16Arg, eight with Arg16Gly, and eight with Gly16Gly genotypes. Tables 2 and 3 show physical features and IOP pressures among subjects according to Arg16Gly mutations. The limited number of subjects with Arg16Arg genotype (n = 3) meant that statistical analyses could not be applied to this group.

No statistical difference was found for weight, height, body mass index or VO<sub>2max</sub> between subjects with the Arg16Gly and Gly16Gly (Table 2) genotypes. Subjects with the Arg16Gly genotype demonstrated a statistically significant reduction in IOP in both eyes immediately post-exercise (P < 0.02), although by 10.00, mean IOP values were returning to pre-exercise levels. Subjects with Gly16Gly also demonstrated a statistically significant reduction (P < 0.02) in mean IOP in both eyes after exercise, but recovery of IOP to pre-exercise levels took

TABLE 2:

Distribution of the Arg16Gly polymorphism and physical and metabolic characteristics of subjects

Physical and metabolic	Ara16Ara	Ara16Glv	Glv16Glv	
characteristics	n = 3	n = 8	n = 8	P-value
Height (cm)	175.33 ± 7.51	181.13 ± 4.22	180.25 ± 8.03	NS
Body weight (kg)	71.00 ± 14.73	73.00 ± 5.71	$74.88\pm8.98$	NS
Mean age (years)	24.00 ± 3.61	21.88 ± 2.47	22.75 ± 3.01	NS
BMI (kg/m²)	22.91 ± 2.78	22.23 ± 1.25	22.99 ± 1.71	NS
VO <sub>2max</sub> (ml/kg per min)	50.67 ± 4.80	49.89 ± 3.41	47.68 ± 2.48	NS
All data are mean $\pm$ SD. NS, not significant. P > 0.05: one-way ANOVA to	-st			

TA	BL	Ε	3:

Intraocular pressures recorded in subjects pre- and post-exercise, according to genotype

		Intraocular pressure (mmHg)				
Genotype	Eyes	Before exercise (09.00)	Immediately post-exercise	10.00	12.00	16.00
Arg16Arg	Right	12.33 ± 1.53	6.00 ± 1.00	9.67 ± 0.58	$\begin{array}{c} 10.67 \pm 2.08 \\ 10.33 \pm 2.08 \end{array}$	11.67 ± 0.58
( <i>n</i> = 3)	Left	11.67 ± 2.08	8.67 ± 3.06	9.00 ± 1.00		11.67 ± 0.58
Arg16Gly	Right	11.75 ± 2.71	8.38 ± 1.69**	11.13 ± 2.47	12.13 ± 1.73	12.50 ± 0.76
( <i>n</i> = 8)	Left	11.75 ± 2.43	9.13 ± 3.04**	11.13 ± 2.10	12.63 ± 1.60	13.13 ± 0.83
Gly16Gly	Right	13.13 ± 2.03	7.63 ± 2.33**	11.25 ± 2.12**	10.38 ± 2.13*	12.88 ± 1.81
( <i>n</i> = 8)	Left	13.63 ± 1.30	7.50 ± 2.39**	11.00 ± 1.77**	11.25 ± 2.05*	12.38 ± 2.13

All data are mean  $\pm$  SD.

\*P < 0.05; \*\*P < 0.02 (Wilcoxon matched-pair signed-rank test).

> 2.5 h (P < 0.05, Table 3) and there was a greater decrease in IOP immediately post-exercise (Table 3).

## Discussion

Compared to individuals with the Arg16Gly genotype, our study showed that it took at least 2.5 h for IOP to return to baseline values in subjects with the Gly16Gly genotype after acute dynamic exercise, therefore an association between post-exercise IOP levels and Gly16Gly  $\beta_2$ AR gene polymorphism is postulated. The  $\beta_2$ ARs are membrane-bound G protein-coupled receptors, which transmit signals after binding of their ligands, epinephrine or norepinephrine.

Green *et al.*<sup>23</sup> found that the polymorphism of the human  $\beta_2AR$  gene alters agonistpromoted down-regulation: polymorphisms created by site-directed mutagenesis of cloned human  $\beta_2AR$  cDNA were expressed in Chinese hamster fibroblasts. They also proposed that these polymorphisms may be responsible for inter-individual variations in expression, regulation, and functional properties of  $\beta_2ARs$ .

The present study is the first to evaluate the mechanism of post-exercise decreases in IOP in terms of  $\beta_2 AR$  gene polymorphism expression, which also implies that variations exist in response to circulating catecholamines. Endogenous catecholamines may induce down-regulation phenotypes,<sup>22</sup> therefore receptor function could be altered by amino-terminal receptor polymorphism.<sup>22,25</sup> The  $\beta_2$ -AR gene polymorphism influences physical activity and antropometric variables,<sup>26</sup> and studies that demonstrate how gene-exercise relations the treatment of chronic regulate ophthalmic disease are warranted:  $\beta_2 AR$ polymorphism may be disease-modifying (treatment for conditions such as

asthma,<sup>17,20,27,28</sup> diabetes mellitus,<sup>29,30</sup> hypertension,<sup>31</sup> myasthenia gravis,<sup>32</sup> congestive heart disease,<sup>33</sup> and obesity<sup>30</sup> can be affected).

Many reports demonstrate that exercise lowers IOP in healthy subjects and people with glaucoma, 4,23,34 - 39 although the exact mechanism of exercise-induced ocular hypotension remains unclear. Several concepts have been proposed: increases in blood lactate levels, plasma osmolarity and reductions in blood pH are associated with decreasing IOP after short-term exercise in humans and rabbits,<sup>6,8,11</sup> although a study comparing aerobic and anaerobic exercise found no statistically significant IOP decrease, despite significant differences in blood pH and lactate levels between the study groups.8 This paper concluded that parameters other than decreasing blood pH and increasing blood lactate levels are responsible for much of the decrease in IOP that is associated with dynamic exercise.8 The effect of continuous and increasingly difficult periods of standardized, submaximal workload on IOP were evaluated in another paper, reporting that two opposing mechanisms affect IOP changes during exertion: a fall in IOP secondary to physiological changes produced during exercise, and a negative feedback response causing a compensatory rise in decreased IOP.<sup>2</sup>

Acute, dynamic exercise may reduce IOP by three possible mechanisms:<sup>11</sup> first, increased blood colloid osmotic pressure may dehydrate the eye through the retinal and uveal vascular structure; secondly, an increase in colloid osmotic pressure may decrease aqueous formation through reduced ultrafiltration; thirdly, colloid osmotic mav affect pressure the hypothalamus, with IOP changes caused by reflex responses.<sup>11</sup> One could hypothesize that acute exercise may decrease IOP by increasing the plasma colloid osmotic pressure, which is associated with changes in iso-osmotic extracellular volume.

Another study focused on the outflow facility of aqueous humour or episcleral venous pressure to explain decreases in IOP after acute, dynamic exercise.<sup>40</sup> An association between IOP and episcleral venous pressure has also been reported,<sup>41</sup> although another study found no significant association between IOP and episcleral venous pressure or outflow facility.<sup>40</sup>

Exercise conditioning, together with glaucoma medication, has also been shown to decrease IOP: Era *et al.*<sup>4</sup> concluded that physical activity may lower IOP, particularly in subjects with high pre-exercise values, although no association between changes in IOP and blood lactate levels was identified in this study. The authors demonstrated this effect among subjects in whom glaucoma had not been diagnosed, as well as patients receiving hypotensive glaucoma medication.<sup>4</sup>

Many clinical and experimental studies have tried to explain the mechanism of IOP decrease during and after exercise, but no single mechanism has been proposed as the primary cause. Our finding suggests that subjects with Gly16Gly genotype show significantly longer periods of decreased IOP than subjects with the Arg16Gly variant, which supports the receptor down-regulation properties of Gly16Gly. This finding may provide additional support in investigations implying a role of circulating catecholamines on IOP drop after dynamic exercise, in addition to other parameters studied.

Gene expression may also be influenced by changes caused by exercise that moderate nuclear-protein binding or relocation of transcription factors to the nucleus.<sup>42</sup> Investigations on the cellular and molecular basis of gene–exercise interactions will explore the mechanism and treatment of glaucoma coupled with exercise conditioning.  $\beta_2$ AR is acknowledged as an important target of drugs and endogenous substances, therefore polymorphisms in this receptor may explain differences in treatment response and disease-modifying conditions.<sup>24,43</sup>

In conclusion, we believe that investigations on the cellular and molecular basis of gene-exercise interactions will help to explore the mechanism and treatment of glaucoma in the light of exercise conditioning. These observations reinforce the concept that  $\beta_2$ AR stimulation during exercise may be an important regulatory factor in daily IOP variations. As a result,  $\beta_2 AR$  polymorphism may provide a useful contribution to understanding the treatment of certain ophthalmic diseases, such as glaucoma.

• Received for publication 20 June 2001 • Accepted 28 June 2001 ©2002 Cambridge Medical Publications

#### References

- 1 Lempert P, Cooper KH, Culver JF, Tredici TJ: The effect of exercise on intraocular pressure. *Am J Ophthalmol* 1967; **63**: 1673 1676.
- 2 Shapiro A, Shoenfeld Y, Shapiro Y: The effect of standardised submaximal workload on intraocular pressure. Br J Ophthalmol 1978; 62: 679 – 681.
- 3 Passo MS, Goldberg L, Elliot DL, Van Buskirk EM: Exercise training reduces intraocular pressure among subjects suspected of having glaucoma. Arch Ophthalmol 1991; **109**: 1096 – 1098.
- 4 Era P, Parssinen O, Kallinen M, Suominen M: Effect of bicycle ergometer test on intraocular pressure in elderly athletes and controls. *Acta Ophthalmol Scand* 1993; **71**: 301 – 307.
- 5 Qureshi IA: The effects of mild, moderate, and severe exercise on intraocular pressure in glaucoma patients. *Jpn J Physiol* 1995; **45**: 561 – 569.
- 6 Marcus DF, Krupin T, Podos SM, Becker B: The effect of exercise on intraocular pressure. II. Rabbits. *Invest Ophthalmol Vis Sci* 1970; **9**: 753 757.
- 7 Leighton DA, Philips CI: Effect of moderate

exercise on the ocular tension. Br J Ophthalmol 1970; **54**: 599 – 605.

- 8 Kielar RA, Teraslinna P, Rowe DG, Jackson J: Standardised aerobic and anaerobic exercise: differential effects on intraocular tension, blood pH, and lactate. *Invest Ophthalmol Vis Sci* 1975; 14: 782 – 785.
- 9 Qureshi IA: Effects of exercise on intraocular pressure in physically fit subjects. *Clin Exp Pharmacol Physiol* 1996; **23:** 648 652.
- 10 Qureshi IA, Wu XD, Xi XR, Yang J, Huang YB: Resting intraocular pressure of steel factory workers is related to their physical fitness. *Ind Health* 1997; **35**: 259 – 263.
- 11 Martin B, Harris A, Hammel T, Malinovsky V: Mechanisms of exercise-induced ocular hypotension. *Invest Ophthalmol Vis Sci* 1999; **40**: 1011 – 1015.
- 12 Borsheim E, Bahr R, Hostmark AT, Knardahl S: Effect of  $\beta$ -adrenoceptor blockade on postexercise oxygen consumption and triglyceride/ fatty acid cycling. *Metabolism* 1998; **47**: 439 – 448.
- 13 Borsheim E, Bahr R, Knardahl S: Effect of  $\beta$ -adrenoceptor stimulation on oxygen consumption and triglyceride/fatty acid cycling after exercise. Acta Physiol Scand 1998; 164: 157 166.
- 14 Wax MB, Molinoff PB. Distribution and properties of beta-adrenergic receptors in human iris-ciliary body. *Invest Ophthalmol Vis Sci* 1987; **28**: 420 – 430.
- 15 Ferrari-Dileo G: Beta-one and beta-two adrenergic binding sites in bovine retina and retinal blood vessels. *Invest Ophthalmol Vis Sci* 1988; **29**: 695 699.
- 16 Mittag TW: Adrenergic and dopaminergic drugs in glaucoma. In: *The Glaucomas* (Ritch R, Shields MB, Krupin T, eds). St Louis: Mosby, 1996; pp1409 1424.
- 17 Liggett SB: Polymorphisms of the beta-2 adrenergic receptor and asthma. Am J Respir Crit Care Med 1997; **156**: S156 – S162.
- 18 Kobilka BK, Dixon RAF, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, et al: CDNA for the human beta-2 adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-deriver growth factor. Proc Natl Acad Sci U S A 1987; 84: 46 – 50.
- 19 Hall IP:  $\beta_2$ -adrenoceptor polymorphisms: are they clinically important? *Thorax* 1996; **51**: 351 353.
- 20 Reihsaus E, Innis M, MacIntyre N, Liggett SB: Mutations in the gene encoding for the  $\beta_2$ -adrenergic receptor in normal and asthmatic subjects. *Am J Respir Cell Mol Biol* 1993; **8**: 334 – 339.
- 21 Turki J, Pak J, Green SA, Martin RJ, Liggett SB: Genetic polymorphisms of the  $\beta_2$ -adrenergic receptor in nocturnal and nonnocturnal asthma. J Clin Invest 1995; **95**: 1635 – 1641.

- 22 Green SA, Turki J, Innis M, Liggett SB: A polymorphism of the human  $\beta_2$ -adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. *J Biol Chem* 1993; **268**: 23116 23121.
- 23 Green SA, Cole G, Jacinto M, Innis M, Liggett SB: Amino-terminal polymorphisms of the human  $\beta_2$ -adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; **33**: 9414 9419.
- 24 Aynacioglu AS, Cascorbi I, Güngör K, Ozkur M, Bekir N, Roots I, *et al*: Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the  $\beta_2$ -adrenergic receptor among Turks. Br J Clin Pharmacol 1999; **48**: 761 – 764.
- 25 Wagoner LE, Craft LL, Singh B, Suresh DP, Zengel PW, McGuire N, *et al*: Polymorphisms of the  $\beta_2$ -adrenergic receptor determine exercise capacity in patients with heart failure. *Circ Res* 2000; **86**: 834 – 840.
- 26 Meirhaeghe A, Helbecque N, Cottel D, Amouye P:  $\beta_2$ -adrenoceptor gene polymorphism, bodyweight, and physical activity. *Lancet* 1999; **353**: 896.
- 27 Martinez FD, Graves PE, Baldini M, Solomon S, Erickson S: Association between genetic polymorphism of the beta-2 adrenoceptor and response to alburetol in children with and without a history of wheezing. J Clin Invest 1997; **100**: 3184 – 3188.
- 28 Tan S, Hall IP, Dewar J, Dow E, Lipworth B: Association between beta-2 adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. *Lancet* 1997; 350: 995 – 999.
- 29 Yamada K, Ishiyama-Shigemoto S, Ichikawa F, Yuan X, Koyanagi A, Koyama W, et al: Polymorphism in the 5'-leader cistron of the  $\beta_2$ -adrenergic receptor gene associated with obesity and type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 1754 – 1757.
- 30 Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K: Association of polymorphisms in the  $\beta_2$ -adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. *Diabetologia* 1999; **42**: 98 101.
- 31 Bray MS, Krushkal J, Li L, Ferrell R, Kardia S, Sing CF, *et al*: Positional genomic analysis identifies the  $\beta_2$ -adrenergic receptor gene as a susceptibility locus for human hypertension. *Circulation* 2000; **101**: 2877 – 2882.
- 32 Xu BY, Huang D, Pirskanen R, Levfert AK:  $\beta_2$ -adrenergic receptor gene polymorphisms in myasthenia gravis (MG). Clin Exp Immunol 2000; **119**: 156 160.
- 33 Liggett SB Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA: The Ile 164  $\beta_2$ -adrenergic receptor polymorphism adversly affects the outcome of congestive heart failure. *J Clin Invest* 1998; **102:** 1534 – 1539.

#### K Güngör, H Beydağı, N Bekir *et al.* Intraocular pressure: $\beta_2$ -adrenergic receptor polymorphism

- 34 Shapiro A, Wolf E, Ferber I, Merin S: The effect of physical activity in the intraocular pressure of glaucomatous patients. *Eur J Appl Physiol* 1983; **52**: 136 – 138.
- 35 Harris A, Arend O, Bohnke K, Kroepfl E, Danis R, Martin B: Retinal blood flow during dynamic exercise. *Graefes Arch Clin Exp Ophthalmol* 1996; 234: 440 444.
- 36 Kergoat H, Forcier P: Correlation of an exerciseinduced increase in systemic circulation with neural retinal function in humans. *Doc Ophthalmol* 1996; **92**: 145 – 157.
- 37 Erb C, Brody S, Rau H: Effect of mental and physical stress on intraocular pressure – a pilot study (in German). *Klin Monatsbl Augenheilkd* 1998; **212**: 270 – 274
- 38 Movaffaghy A, Chamot SR, Petrig BL, Riva CE: Blood flow in the human optic nerve head during

isometric exercise. Exp Eye Res 1998; 67: 561 – 568.

- 39 Avunduk AM, Yilmaz B, Sahin N, Kapicioglu Z, Dayanir V: The comparison of intraocular pressure reductions after isometric and isokinetic exercises in normal individuals. *Ophthalmologica* 1999; **213**: 290 – 294.
- 40 Stewart RH, LeBlanc R, Becker B: Effects of exercise on aqueous dynamics. *Am J Ophthalmol* 1970; **69**: 245 248.
- 41 Podos S, Minas T, Moori F: A new instrument to measure episcleral venous pressure. Arch Ophthalmol 1968; **80**: 209 – 211.
- 42 Bray MS: Genomics, genes, and environmental interaction: the role of exercise. *J Appl Physiol* 2000; **88**: 788 792.
- 43 Liggett SB: Molecular and genetic basis of the  $\beta_2$ -adrenergic receptor function. J Allergy Clin Immunol 1999; **103**: S42 S46.

Address for correspondence Dr K Güngör Fatih Mah, 33 Sok, No: 4 Daire 7, Sevgi Apt. Sehitkamil, Gaziantep, Turkey 27070. E-mail: gulenkg@superonline.com